Yi Larson Net Worth

The estimated Net Worth of Yi Larson is at least $13.9 Milione dollars as of 1 February 2021. Ms. Larson owns over 30,000 units of Turning Point Therapeutics Inc stock worth over $1,292,322 and over the last 5 years she sold TPTX stock worth over $0. In addition, she makes $12,579,400 as Chief Financial Officer e Executive Vice President at Turning Point Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Larson TPTX stock SEC Form 4 insiders trading

Yi has made over 2 trades of the Turning Point Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 30,000 units of TPTX stock worth $1,620,900 on 1 February 2021.

The largest trade she's ever made was exercising 30,000 units of Turning Point Therapeutics Inc stock on 1 February 2021 worth over $1,620,900. On average, Yi trades about 3,222 units every 51 days since 2019. As of 1 February 2021 she still owns at least 17,002 units of Turning Point Therapeutics Inc stock.

You can see the complete history of Ms. Larson stock trades at the bottom of the page.

Yi Larson biography

Yi Larson serves as Chief Financial Officer, Executive Vice President of the Company. Ms. Larson previously worked at Goldman Sachs & Co. LLC where she has held various roles since 2008, most recently as Managing Director of Healthcare Investment Banking since January 2018. During her tenure at Goldman Sachs & Co. LLC, Ms. Larson worked with a variety of biotechnology company boards of directors and management teams on a range of strategic financial matters, including capital and financing strategy, public stock offerings and other financings, and buy- and sell-side transactions. Ms. Larson graduated from The Wharton School at the University of Pennsylvania with a master’s degree in Business Administration concentrated in Finance. She also earned a master’s degree in Electrical Engineering and Computer Science and a bachelor’s degree in Electrical Engineering, both from the Massachusetts Institute of Technology.

What is the salary of Yi Larson?

As the Chief Financial Officer e Executive Vice President of Turning Point Therapeutics Inc, the total compensation of Yi Larson at Turning Point Therapeutics Inc is $12,579,400. There are no executives at Turning Point Therapeutics Inc getting paid more.

How old is Yi Larson?

Yi Larson is 40, she's been the Chief Financial Officer e Executive Vice President of Turning Point Therapeutics Inc since 2019. There are 18 older and 1 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.

What's Yi Larson's mailing address?

Yi's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.

Insiders trading at Turning Point Therapeutics Inc

Over the last 5 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado e Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.

What does Turning Point Therapeutics Inc do?

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Complete history of Ms. Larson stock trades at Turning Point Therapeutics Inc e Olema Pharmaceuticals

Turning Point Therapeutics Inc executives and stock owners

Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include:

• Yi Larson,
  Chief Financial Officer, Executive Vice President
• Mohammad Hirmand,
  Executive Vice President, Chief Medical Officer
• Annette North,
  Executive Vice President, General Counsel, Secretary
• Dr. Athena Maria Countouriotis M.D.,
  Pres, CEO & Director
• Andrew John Partridge,
  Exec. VP & Chief Commercial Officer
• Carol Gallagher,
  Independent Director
• Dr. Mohammad Hirmand,
  Exec. VP & Chief Medical Officer
• Patrick Machado,
  Independent Director
• Annette C. North Esq., LLB,
  Exec. VP, Gen. Counsel & Company Sec.
• Dr. Siegfried Reich Ph.D.,
  Exec. VP & Chief Scientific Officer
• Simeon George,
  Independent Director
• Sheila Gujrathi,
  Chairman of the Board
• Jacob Chacko,
  Independent Director
• Jim Mazzola,
  IR Contact Officer
• Garry Nicholson,
  Independent Director
• Heather Adams,
  Vice President of Human Resources
• Brian Baker,
  Vice President - Finance and Administration
• Siegfried Reich,
  Executive Vice President, Chief Scientific Officer
• Athena Countouriotis,
  President, Chief Executive Officer, Director
• Dr. Jeffrey P. Whitten,
  Sr. VP of Pre-Clinical Devel.
• Brian Sun J.D., M.S.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Dr. Gavin Hirst Ph.D.,
  Sr. VP of Chemistry & Interim Chief Scientific Officer
• Raymond J. Furey J.D.,
  Sr. VP & Chief Compliance Officer
• Dr. Adam D. Levy M.B.A., Ph.D.,
  Sr. VP of Investor Relations & Corp. Communications
• Ed Gemo,
  Sr. VP & Chief Information Officer
• Kyri K. Van Hoose,
  VP of Accounting & Interim Principal Accounting Officer
• Paolo Tombesi,
  Exec. VP & CFO
• Jingrong Jean Cui,
  Director
• Plc Gsk,
  Director
• Hongbo Lu,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Asset Management, Lp Chen B...,
  
• Carl L Gordon,
  Director
• Barbara W. Bodem,
  Director
• Mark J Alles,
  Director
• Paolo Tombesi,
  EVP & Chief Financial Officer
• Brian Sun,
  SVP & General Counsel
• Steve M Sabus,
  SVP & Chief Commercial Officer